No­vavax says up­dat­ed Covid-19 jab works against two sub­vari­ants; Ul­ti­movacs re­vis­es PhII can­cer vac­cine read­out

No­vavax said that its up­dat­ed XBB-tar­get­ing Covid-19 vac­cine showed neu­tral­iz­ing an­ti­body re­sponse to­ward XBB sub­vari­ants EG.5.1 and XBB.1.16.6.

The ex­act specifics of the da­ta, ob­tained from small an­i­mal and non-hu­man pri­mate stud­ies, re­main undis­closed. The biotech added that XBB sub­lin­eage vari­ants make up the ma­jor­i­ty of Covid-19 cas­es in the US and the EU.

The com­pa­ny re­vealed ear­li­er this month it was plan­ning to fin­ish fil­ing its up­dat­ed vac­cine to the FDA by the end of Au­gust in a bid to get it on the mar­ket by Sep­tem­ber for the fall vac­ci­na­tion sea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER